Esophageal Cancer Clinical Trials

• Self-identifies as a member of racial and/or ethnic minority populations as defined by the Food and Drug Administration (FDA), such as Black or African American, Hispanic or Latino, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander

• Histologically confirmed, locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma (GAC/GEA) or esophageal squamous cell carcinoma (ESCC)

• No previous systemic therapy for locally advanced unresectable or metastatic GAC/GEA or ESCC

• At least 1 measurable lesion per RECIST v1.1 as determined by investigator assessment

• Patients must have positive tumor programmed death-ligand 1 (PD-L1) expression. Documented PD-L1 results are acceptable

• Eastern Cooperative Oncology Group (ECOG) Performance Status score ≤ 1

• Adequate organ function as indicated by the following laboratory values ≤ 14 days prior to study treatment

• Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and ≥ 120 days after the last dose of tislelizumab and ≥ 180 days after the last dose of chemotherapy, and have a negative urine or serum pregnancy test ≤ 7 days prior to study treatment

• Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of tislelizumab and ≥ 180 days after the last dose of chemotherapy